Tommy Li

580 total citations · 1 hit paper
15 papers, 389 citations indexed

About

Tommy Li is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Tommy Li has authored 15 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Immunology. Recurrent topics in Tommy Li's work include CAR-T cell therapy research (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Biosimilars and Bioanalytical Methods (7 papers). Tommy Li is often cited by papers focused on CAR-T cell therapy research (14 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Biosimilars and Bioanalytical Methods (7 papers). Tommy Li collaborates with scholars based in United States, Netherlands and Denmark. Tommy Li's co-authors include Roberto S Oliveri, Dena DeMarco, Tahamtan Ahmadi, Christopher Chiu, Brian Elliott, Martin Hutchings, Kim Linton, Anna Sureda, David Cunningham and Michael Roost Clausen and has published in prestigious journals such as The Lancet, Blood and Cancer Research.

In The Last Decade

Tommy Li

14 papers receiving 386 citations

Hit Papers

Dose escalation of subcutaneous epcoritamab in patients w... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
    2021 212 citations Martin Hutchings, Rogier Mous et al. The Lancet profile →

Peers

Tommy Li
Aleš Obr Czechia
Sandrine Payrard France
Reid W. Merryman United States
Jennifer L. Cultrera United States
David Sermer United States
A McClure United Kingdom
Suzanne Fanning United States
Sandra P. Susanibar-Adaniya United States
Noboru Yonetani Japan
Aleš Obr Czechia
Tommy Li
Citations per year, relative to Tommy Li Tommy Li (= 1×) peers Aleš Obr

Countries citing papers authored by Tommy Li

Since Specialization
Citations

This map shows the geographic impact of Tommy Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tommy Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tommy Li more than expected).

Fields of papers citing papers by Tommy Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tommy Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tommy Li. The network helps show where Tommy Li may publish in the future.

Co-authorship network of co-authors of Tommy Li

This figure shows the co-authorship network connecting the top 25 collaborators of Tommy Li. A scholar is included among the top collaborators of Tommy Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tommy Li. Tommy Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Li, Tommy, Leonid Gibiansky, Apurvasena Parikh, et al.. (2025). Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma. Clinical Pharmacology & Therapeutics. 117(5). 1437–1450. 1 indexed citations
2.
Dandamudi, Durga Bhavani, Iwona Konieczna, Paul A. Ellis, et al.. (2025). Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma. Leukemia & lymphoma. 66(9). 1688–1699.
3.
Li, Tommy, Leonid Gibiansky, Apurvasena Parikh, et al.. (2024). Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. Clinical Pharmacokinetics. 64(1). 127–141. 2 indexed citations
4.
Shah, Nirav N., Martin Lechmann, Hardik Mody, et al.. (2024). Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy. Clinical Pharmacology & Therapeutics. 117(1). 34–55. 2 indexed citations
5.
Li, Tommy, Leonid Gibiansky, Apurvasena Parikh, et al.. (2023). Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood. 142(Supplement 1). 4481–4481. 1 indexed citations
6.
Li, Tommy, Leonid Gibiansky, Apurvasena Parikh, et al.. (2023). Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood. 142(Supplement 1). 3135–3135. 3 indexed citations
7.
Li, Tommy, Craig J. Thalhauser, Apurvasena Parikh, et al.. (2023). Abstract 2798: Simplifying selection and optimization of step-up dosing of subcutaneous Epcoritamab to mitigate CRS risk using repeated time-to-event modeling. Cancer Research. 83(7_Supplement). 2798–2798. 6 indexed citations
8.
9.
Vose, Julie M., Tatyana Feldman, Martine E.D. Chamuleau, et al.. (2023). Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1. Blood. 142(Supplement 1). 1729–1729. 9 indexed citations
10.
Li, Tommy, Ida H. Hiemstra, Christopher Chiu, et al.. (2022). Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas. Clinical Pharmacology & Therapeutics. 112(5). 1108–1119. 25 indexed citations
11.
Konieczna, Iwona, Apurvasena Parikh, Tommy Li, et al.. (2022). Evaluation of Epcoritamab and Rituximab Combination in Preclinical Models of B-Cell Non-Hodgkin's Lymphoma (NHL). Blood. 140(Supplement 1). 9283–9285. 4 indexed citations
12.
Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet. 398(10306). 1157–1169. 212 indexed citations breakdown →
13.
Kater, Arnon P., Jacob Haaber Christensen, Hans Bentzen, et al.. (2021). Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial. Blood. 138(Supplement 1). 2627–2627. 13 indexed citations
14.
Lala, Mallika, Tommy Li, Dinesh P. de Alwis, et al.. (2020). A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. European Journal of Cancer. 131. 68–75. 106 indexed citations
15.
Li, Tommy, Ida H. Hiemstra, Roberto S Oliveri, et al.. (2020). Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20). Blood. 136(Supplement 1). 35–36. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aleš Obr Breakdown of academic impact, for papers by Sandrine Payrard Breakdown of academic impact, for papers by Reid W. Merryman Breakdown of academic impact, for papers by Jennifer L. Cultrera Breakdown of academic impact, for papers by David Sermer Breakdown of academic impact, for papers by A McClure Breakdown of academic impact, for papers by Suzanne Fanning Breakdown of academic impact, for papers by Sandra P. Susanibar-Adaniya Breakdown of academic impact, for papers by Noboru Yonetani
Rankless by CCL
2026